Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

STTKBullishEarningsShort Term

High materiality8/10

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

StockNews.AIAug 11, 6:15 AM EDT1 source

Trading thesisImportance 8/10

Bullish near-term as Crohn's Phase 2b start and SL-846 milestones drive upside, with cash runway support.

AI summary

What happened and why it matters

Shattuck Labs reported Q2 2026 results with SL-325 Phase 1 data showing favorable safety, strong immunogenicity profile, and durable TL1A-DR3 blockade, supporting quarterly maintenance dosing. The RECEPTIVE-CD1 Crohn's trial is slated to begin in Q3 2026, while SL-846 data is anticipated in 2027. The company ended the period with $208.3 million in cash and equivalents, providing runway into 2029 and preserving optionality for pipeline expansion.

Phase 2b Crohn’s trial initiation in Q3 2026 may trigger upside in STTK.
Phase 1 SL-325 durability and safety data could broaden multi-indication potential.
Cash runway to 2029 reduces near-term dilution risk and supports R&D progress.
Upcoming investor conferences may amplify visibility and catalysts.

Sentiment rationale

Clinical progress (Phase 2b start) and strong Phase 1 signals for SL-325, plus SL-846 IND-enabling progress, could drive a re-rating. Cash runway to 2029 reduces dilution risk; multiple upcoming investor events add liquidity and visibility. Historical biotech catalysts around Phase 2b starts commonly produce outsized moves, though execution risk remains.

Key facts

01
SL-325 Phase 1 shows favorable safety and best-in-mechanism immunogenicity; durable TL1A-DR3 blockade.
02
Blockade persists >3 months at 1 mg/kg+, enabling quarterly maintenance dosing.
03
RECEPTIVE-CD1 Phase 2b Crohn's trial expected to start in Q3 2026 with 232 patients.
04
SL-846: DR3 x IL-23R bispecific; IND-enabling, phase data expected 2027.
05
Cash and equivalents/investments: $208.3 million as of 6/30/2026; runway to 2029.

Earnings

Category: Earnings and Corporate Developments. The release combines quarterly results with pipeline milestones, signaling near-term clinical catalysts and a defined cash runway, which are critical for STTK's value trajectory.